Triple Negative Breast Cancer Whole Blood

<h2>Triple Negative Breast Cancer Whole Blood for Research</h2>
Triple negative breast cancer (TNBC) lacks estrogen, progesterone, and HER2 receptor expression, making it more aggressive and reliant on chemotherapy and emerging immunotherapy approaches. Sanguine collects fresh whole blood from IRB-consented donors with a clinically confirmed TNBC diagnosis for oncology biomarker research.
<h3>Product Features</h3>
<ul><li>Fresh whole blood from clinically diagnosed TNBC donors</li><li>Custom anticoagulants and collection tubes available</li><li>Same-day collection and shipment</li><li>Research Use Only (RUO)</li></ul>
<h3>De-identified Donor Data</h3>
<ul><li>Physician-confirmed TNBC diagnosis, including BRCA status where available</li><li>Demographics: age, sex assigned at birth, ethnicity</li><li>Relevant medical and treatment history</li></ul>
<h3>Applications</h3>
<ul><li>BRCA1/2 and genomic risk-variant analysis</li><li>Circulating tumor DNA and liquid-biopsy studies</li><li>Gene expression and transcriptomic analysis</li><li>Immunotherapy and chemotherapy response research</li></ul>
<h3>Compliance and Quality</h3>
<ul><li>IRB-approved protocols and electronic informed consent</li><li>HIPAA-compliant donor data handling</li></ul>
<h3>Ordering and Customization</h3>
TNBC whole blood is available in standard and custom volumes. Email <a href=”mailto:learnmore@sanguinebio.com”>learnmore@sanguinebio.com</a> for international orders or documentation requirements.